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Since 1980, the lung function of cystic ﬁbrosis (CF)
patients in the Cystic Fibrosis Foundation Patient Registry
has shown steady improvement and birth cohorts since
1985 have retained forced expiratory volume in one second
(FEV1) ≥90% predicted into adolescence [1]. Despite this
improvement, our goal must be normal survival and quality
of life for all our patients no matter how ambitious this
goal may be. According to available data, the life expectancy
and prognosis for CF patients varies considerably among
countries and even among clinics within a single country.
Although many factors may account for these differences, not
all can be attributed to the gene pool, local referral strategy, or
clinical trials with revolutionary new treatments! In fact, most
of us have access to the same therapeutic armamentarium.
Why then do patients in some countries or clinics have better
outcomes than others?
The answer must lie, not only in economic differences, but
in large part also in different treatment strategies. Now that
pulmonary care guidelines for CF have been established by
our peers in several countries, we need to address how well
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our own practice adheres to these guidelines, and constantly
strive to deliver the best available care to our own patients.
Reliance on evidence-based medicine where it exists in CF,
as well as benchmarking our practices and outcomes against
those of similar centres, should allow us to deliver the care
that best meets patients’ expectations.
This symposium introduces how we can strive for excel-
lence in the care we deliver today, as we await promising new
treatments. It also presents some recent studies on optimising
administration of dornase alfa (Pulmozyme®), and reviews
risk factors for poor prognosis and how we can address them
on an individual patient basis.
In summary, this symposium focuses on how to develop an
eye for the details of CF care that matter.
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